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ABSTRACT
Delivering effective and non-toxic doses of bioactive materials that can aid in activating
tissue regeneration to wounded tissue has proven to be an enormous challenge. This study was
designed to produce a potential therapeutic recombinant protein by fusing two collagen binding
domains to basic fibroblast growth factors (bFGF) through a collagenase cleavage site linker, so it
can release the bFGF in a wound site by the action of this enzyme. The novel fusion protein was
expressed in Escherichia coli BL-21 (E. coli) using traditional flask shaker and fed-batch
cultivation. Cell lysate was purified by FPLC using Immobilized metal affinity chromatography
and heparin heparin-affinity chromatography. Results showed that the desired fusion protein was
expressed, but different truncated products were also evident including a protease within E.coil
may indeed recognize the designed collagenase cleavage site sequence.
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1. Overview
This study is designed to express a novel therapeutic recombinant protein by fusing two collagen
binding domains to basic fibroblast growth factors bFGF with a collagenase cleavage site linker.
Collagen-binding domain serves as a shuttle to deliver effective nontoxic doses of fibroblast
growth factors bFGF to the wound site. Hisx6-tag has been placed at N-termnial to facilitate
purification by immobilized metal affinity chromatography. Also, heparin-affinity
chromatography purification has been performed in the investigation experiment to prove our
hypothesis surrounding a cleavage issue of bFGF after the production of fused protein.
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2. Literature Review
2. 1. Proteins
Proteins are essential macromolecules in living systems and serve diverse functions in all
biological processes ranging from DNA replication [1], metabolic processes in the cell, transport
and storage, mechanical support and immune protection, and movement, transmitting nerve
impulses, growth control and differentiation, as well as the converting one molecule into another
[2, 3].
The word "protein," is derived from the Greek adjective proteios, meaning the class of
organic compounds that is present in all living cells in different forms such as skin, hair, callus,
cartilage, muscles, tendons and ligaments [4, 5]. The word protein was mentioned for the first
time in 1838 in a letter sent by chemist Jöns Jakob Berzelius to Dutch chemist Gerhardus
Johannes Mulder. Berzelius carried out an elemental analysis of common proteins and found that
nearly all proteins had the same empirical formula. Mulder worked on identifying the products of
protein degradation such as the amino acid leucine which has a molecular weight of 131 Daltons.
During that time, Antoine Fourcroy and other researchers recognized proteins as a different class
of biological molecules that were distinguished by their ability to coagulate or flocculate when
treated with acid or heat [6]. Proteins were discovered to be large macromolecules, they consist
of between 50 to 10,000 residues. Some proteins even exceed one million residues [5, 6]. Since
the average molecular weight of a single residue is 120 Dalton, the approximate protein
molecular weight is anywhere between 10 thousand to a few million Daltons [5, 7]. Proteins are
linear polymers consisting of monomer units of amino acids which are connected by a type of
amide linkage called a peptide bond. Each amino acid in a peptide or protein is called a residue
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[2, 7, 8]. A peptide bond is a bond formed by the reaction of an α-amino group (NH2) of one
amino acid with the carboxyl group (COOH) of another, as shown below in Figure 1 [9].

Figure 2.1 Example of the formation of a peptide bond by a condensation reaction between an αamino group (NH2) of one amino acid with a α-carboxyl group (COOH) of another[10].
A polypeptide is a single linear polymer chain of amino acids bonded together by peptide
bonds between the carboxyl and amino groups of adjacent amino acid residues [9]. Proteins
consist of one or sometime multiple polypeptides which can naturally fold after being
synthesized into a specific three dimensional to form either globular or fibrous protein to do a
biological function [11, 12].
2.2 Overview of protein structure
All proteins are categorized at four levels of structure (primary, secondary, tertiary, and
quaternary) [13]. There are 20 amino acids that exist naturally in living organisms. In some
cases, these amino acids are chemically modified after protein synthesis [1, 2]. It is possible to
build a large number of different proteins from 20 amino acids. For example, 10 different
sequences from 20 amino acids yield approximately 10 trillion of different structures of proteins

3

[5]. The primary structure represents the linear sequence of amino acids residues. Every protein
has a unique sequence of amino acids that is held together by peptide bonds. The primary
structure is defined as a nucleotide sequence of a gene, which is encoded in the genetic code of
messenger RNA for that protein [5, 13]. The secondary structure is formed by the primary
structure which refers to the linear configuration of the amino acids. In this structure, the
repeating amino acid sequence is stabilized by hydrogen bonds between residues that are not
widely separated. There are two types of secondary structure; an alpha helix, and a beta sheet
[14]. An alpha helix is a coiled structure stabilized by hydrogen bonds which form through
interactions between the NH group of one residue and CO group of a neighboring residue.
Basically, the carboxyl group of one residue bind to the amino group of another residue located
four residues down in the amino acid sequence through hydrogen bond. In contrast, hydrogen
bonds can form between parallel chains of polypeptides forming a beta sheet structure. Parallel
beta-sheet structures are more stable than an alpha-helix. Hydrogen bonds between parallel
amino acid chains stabilize the beta sheets allowing flexibility and resistance to damaging its
integrity by being stretched [2, 11, 12].
Proteins also can fold extensively into a more stable complex three-dimensional
configurations called a tertiary structure. This kind of 3D structure is maintained by covalent
bonds, hydrogen bonds, disulfide bonds, ionic bonds, and hydrophobic interactions between R
groups that define each amino acid. The R groups organize in a way that the hydrophobic side
chains are in the interior and the hydrophilic groups are exterior to help form three-dimensional
configuration of a protein [1, 5]. When multiple polypeptide chains join together, they form a
quaternary structure. This structure is known as a protein complex and is formed by disulfide
bonds or relatively weak interactions among the polypeptides in two or more different subunits
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that hold the structure in place. Hemoglobin is an example of a macromolecule with quaternary
structures which consists of four subunits [7].
2. 3. Recombinant protein production
Previously, a large amount of plant and animal tissues or large volumes of biological
ﬂuids were normally used to purify small amounts of a given protein from a natural source.
Those time consuming and complicated methods have been eliminated by expressing
recombinant proteins in microbial systems [15]. Recently, when researchers needed a protein to
use in their project, they immediately think of how to obtain it in a recombinant form rather than
extracted from natural sources. The ability to express and purify the desired recombinant protein
in large quantities allows for its biochemical characterization and to be used for further
application at both a laboratory or industry level [16]. Theoretically, obtaining a recombinant
protein is a straightforward process. It can be done by cloning a gene of interest in the desired
expression vector, and transforming it into the selected host and inducing it to produce the
protein. Following this procedure, the protein is ready for puriﬁcation and characterization
(Figure 2.2). On the other hand, several issues may arise such as slow growth, inclusion body
formation, producing inactive protein or not even producing the protein of interest at all [15, 17].
This research focused on the production and purification of a new basic fibroblast growth
factor fused to two collagen binding domains expressed in E. coli BL21. It is hoped that a
potential therapeutic agent which may aid in wound healing will result from this work.
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Figure 2.2 Schematic overview of the topics covered in this review, highlighting the multiple
parameters (listed on the right) that can greatly impact the success of soluble expression [15].
2.4. Host selection
The choice of host is an important step to produce a recombinant protein. Typically, a
distinctive vector for protein expression, selection marker, and origin of replication are basic
properties to be considered. A successful production process of heterologous proteins depend on
the proper host [18]. On the other hand, the molecular properties of each particular protein such
as protein size and 3D structure affect the selection of the host system. For example, proteins
which have multiple disulfide bonds such as insulin are cloned into an easily fermentable
microorganism, while proteins with one or two of disulfide bonds are typically made in
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eukaryotic systems [19]. Therefore, the suitable expression system for each individual of
recombinant protein products need to be optimized individually.
In general, two major strategies can be used for the expression of heterologous genes:
episomal vectors and chromosomal integration. There are advantages and disadvantages to each
method. High copy number vectors can be used for plasmid (episomal) systems, but antibiotics
are typically required as an addition to the media. In their absence, the plasmid may be lost. In
contrast, chromosomal integration results in a lower copy number, but the gene copies are
maintained in the absence of the selection marker [18]. Previous studies show that both secreted
and intracellular proteins have been successfully expressed at a large scale [20]. There are
several genetically engineered eukaryotic and prokaryotic cells which are capable of expressing a
wide range of recombinant proteins. The most common host for intracellular recombinant protein
expression is Escherichia coli, while mammalian cells are used for extracellular recombinant
protein expression. Yeast especially Saccharomyces cerevisiae can produce both intracellular
and extracellular products [19]. Pharmaceutical industries tend to prefer extracellular protein
production over intracellular proteins due to the difficulties of downstream processing to extract
the target proteins through lysis and chromatography [20]. Prokaryotic systems like Escherichia
coli (E. coli ), which has been used in this study, genetically engineered yeast cells, genetically
engineered fungi, as well as insect and mammalian cells are the main recombinant protein
expression systems used in bio-pharmaceuticals industries [19].
2.4.1 E. coli host strains
Although there are several host systems available for recombinant protein expression, the
preferred choice is E coli as an initial host [21]. It is the most widely used of all prokaryotic
organisms due to its well-known genetic background and unique physiological characterization.
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It is easy to handle and culture at high density on inexpensive substrates with a very short
doubling life cycle time [19, 22, 23]. E. coli is an affordable host that has been used often to
minimize the cost of therapeutic protein production [24, 25]. It has remarkable ability to produce
a large amount of recombinant protein [26]. The ﬁrst recombinant DNA (rDNA) biopharmaceutical, that enabling the approval of Eli Lilly’s rDNA human insulin was produce in E.
coli at 1982 [27].
The most important factor for recombinant expression is the genetic background of the
host. Absence of the most harmful natural proteases in expression strains is very important to
maintain the stability of the plasmid expression level. E. coli BL21[28, 29] is an advantageous
and common strain which has been proven outstanding in standard recombinant expression. It is
an efficient E. coli B strain which can grow in minimal media with high density. The beauty of
this strain is non-pathogenicity which is unlikely survive and cause disease to the host tissue
[30]. BL21 lacks two proteases (ompT and lon) that may attack recombinant proteins after
expression [31, 32]. There are other derivatives of BL21 such as recA negative strains(Novagen
BLR strain) is used for the stabilization of target plasmids holding repetitive sequences, trxB/gor
negative mutants (Novagen Origami and AD494 strains) used mainly for inducing cytoplasmic
disulfide bond formation, lacY mutants (Novagen Tuner series) regulating the adjustable levels
of protein expression and mutants (Avidis C41(DE3) and C43(DE3) strains) used for the soluble
expression of inclusion body and membrane proteins production [28].
Overexpression of heterologous protein in E coli often result in an aggregation form of an
expressed protein called inclusion bodies. Inclusion bodies are known as a large proportion of
the target protein accumulating in dense insoluble aggregates. This generally occurs because of
several factors leading to the formation of partially folded or misfolded protein intermediates in
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cytoplasm such as high local concentration of polypeptide chains emerging from ribosomes and
inefficient folding and unavailability of chaperones [33]. Minimizing inclusion body formation is
preferred to maximize the yield of well-folded active protein in soluble form. Collecting the
insoluble fraction, in some cases, can be used to rebuild and produce large quantities of
biologically active protein. There are several clinically important hormones, and peptides that
have been produced using this approach since the late 1970s [34]. Most pharmaceutical
industries produce recombinant proteins as inclusion bodies using E. coli systems. Complete
denaturation of inclusion bodies, chemical refolding, and purification are required for the
isolation of the active protein form [35, 36]. Despite the difficulty of recovering heterologous
proteins from inclusion bodies, there are several advantages of this phenomenon such as
decreased proteolytic activity and higher yield [19]. Although the methods associated with
insoluble protein production have commercial signiﬁcance, it is still less well developed than the
corresponding methods for the production of the soluble one.
2.5 Plasmid
Plasmids are a biological delivery vector of a small extrachromosomal DNA that can
transfer between prokaryotic and/or eukaryotic host cells. On the other hand, plasmids are a tool
for inserting a foreign gene(s) into the host cells. Inside, the plasmid is able to replicate
independently of host cell replication, however, it utilizes the cell`s contents such as enzymes
and ribosomes for its transcription (mRNA) and translation (amino acids) respectively. Most
plasmids are circular in shape and vary in sizes from 1,000 to 20,000 DNA base pairs. Plasmids
are easy to be opened by restriction enzymes without falling apart. This characterteristic makes it
easy to anneal a new DNA fragment(s) and express these fragment(s). There are many types of
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genetically modified plasmids which are used for the production of recombinant products such as
enzymes, vaccines, and supplements that are applied in different biological fields [37, 38].
2.5.1 Composition of the plasmids
There are very important DNA regions that must be present in the plasmids to be
maintained inside the host cells, replicating spontaneously, and expressing the target gene [39]
(figurer 2.3).

Figure 2.3 General plasmid component in pUC18 plasmid structure as an example [2].
2.5.2 The multiple cloning sites (MCSs)
Multiple cloning sites are also known as polylinkers which contains many unique specific
sequences for different restriction enzyme to open the plasmid to insert and clone the desired
gene to produce the protein of interest [40, 41](Figure 3.2).
2.5.3 The selectable markers
Even when applying modern molecular biology techniques, only very few cells can accept the
plasmids (around one per ten thousand cells). To ensure the plasmids are successfully
transformed into the host cells, the cells supposed to be grown and appear a feature that insert in
10

the plasmids. The most commonly used markers are antibiotic resistance markers [42, 43]. In
case of ampicillin markers, the plasmid carries a beta-lactamase gene which breaks down the
beta-lactam bond; subsequently, deactivating the action of ampicillin when the cells grow in
ampicillin-containing media [44] (Figure 2.4).

Figure 2.4 β-lactam ring is hydrolyzed by bacteria [45].
2.5.4 The origin of replication site (ORI):
The plasmid initiates self-replication at this site to increases in number inside the host cell
[46]. The number of plasmids is determined by the origin replication type. The type of ORI
determines the number of copies. Origin of replication of plasmid pUC19 produces 500 to 700
copies per each bacterial cell whereas, ORI of plasmid pBR322 produce only 15-20 copies [43].
2.5.5 The promotor
It is a stretch of DNA sequenceing that encodes to RNA polymerase sitting directly
before the MCSs. In this place, the plasmid starts its own expression since it contains a binding
site for RNA polymerase. Without induction, the promotor cannot spontaneously start the
expression because the RNA polymerase site is blocked. To open the site, a substance such as
11

IPTG or arabinose are added to the media at a determined time which will cause deformation to
the blocked region, resulting in opening and binding to the RNA polymerase. In case of the
presence of Lac operon, induction is difficult if glucose is used as a metabolizable carbon source
in rich media. Lactose enhance induction of the system for protein expression. Therefore, if
lactose and glucose are present in the media, full induction of the system occurs until the
remaining glucose is consumed [47]. There are eight major promoters used for recombinant
protein expression [48];
1- IPTG-inducible promoters (Lac, LacUV5).
2- The auto inducible trp promoter.
3- The hybrid promoters tac and trc.
4- The heat-inducible phage λ promoters PL and PR.
5- The tetracycline-inducible promoter.
6- The arabinose-inducible PBAD promoter.
7- The cold-inducible cspA promoter.
8- T7 promoter.
2.6 Cultivation strategies
Two culturing strategies have been used reqularly for the production of recombinant
protein; batch and fed-batch cultivations. In the case of batch culture, higher growth rates will
decrease the media efficacy to maintain the same level of growth for longer periods, and acetate
will accumulate at a higher rate. High cell density initiates several issues such as a substrate or
product inhibition, nutrient inhibition, and dissolved oxygen starvation in aerobic conditions [49,
50]. Using fed-batch can minimize certain problems associated with high-density growth and can
be maintained for longer periods of time at faster rate [51]. As in industry, the use of this process
12

aims to scale up protein production in a minimal frame time, fed-batch fermentation should be
done in bioreactors that possess useful hardware such as pH probes to control the production of
biomass instead of using manual control (Figure 2.5). For example, using a probe to control a
pH of 6.0 will lead to a higher biomass growth production [52]. Also, adding other probes that
relate growth to feeding may lead to efficient substrate use [53]. In general, the term "batch" is
often used to refer to both batch and fed-batch fermentation [54].
2.6.1 Batch fermentation
Batch fermentation is an easy to operate, inexpensive, and poses a very low chance of
contamination. Broadening the use of this technique by the researcher should result in
recombinant proteins from bacterial, mammalian, and insect cells with high yields [55]. All
necessary medium components and inoculum should be added at the same time at the beginning
of the process and not during the fermentation process [56]. This technique can be accomplished
by the use of a bioreactor. The difference between using traditional, simple flask method and a
bioreactor in a batch cultivation is the ability to monitor and control. Basically, in flask methods
all culture components include media, bacteria, substrates (that are added at the same time in one
batch for a certain period without any biomass), pH, temperature, and dissolved oxygen monitor
and control [57]. In contrast, biomass, pH, temperature, and dissolved oxygen can be monitored
and controled using the bioreactor method. A host with engineered a plasmid that contains the
DNA of interest are used to inoculate a suitable media in a special, sterile glass tank of
bioreactor. This tank is closed tightly with a steelhead. This head contains a stirrer extending
down close to the bottom of the glass tank to combine the culture component contrary to the
culture shake in flask method. It also has a head plate containing openings that connect an
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oxygen supply, pH electrode, dissolved oxygen and temperature probes (Figure 2.5).

Figure 2.5 Schematic of fed-batch fermentation set-up. The flow of oxygen and acid/base into
the reactor are regulated by tower controls based on signals from probes, Nutrition feed that is
essentially pumped into reactor is controlled using Applikon BioXpert software [59].

All these components connect to a computer loaded with software that monitor and
control, regulating agitator speed and oxygen flow rate, as well as maintaining the optimum heat
and pH level by addition of an acid or base. The advantage of using the bioreactor method is the
cultivation period after plasmid induction to express the target protein. This method allows the
growth to continue for several days compared to flask shaker which is harvested after five to
seven hours from plasmid induction. Plasmid induction for gene expression is carried when
optical density (O.D) at 600 nm reaches about 0.6 which represent the early time of the
exponential phase of the growth [55].
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2.6.2 Fed-batch fermentation
This technique has been used to achieve high cell density to produce a high yield of
recombinant protein. High cell density fermentation is the main target of bioprocess engineering
to increase the yield of recombinant proteins production. It is the main consideration to increase
the protein expression in E. coli [58]. The main differences between batch and fed-batch
processes are materials such as media or carbon sources can be added during the batch run.
Certain issues can arise from increasing cell concentration during cultivation such as a substrate
or product inhibition, nutrient inhibition, or dissolved oxygen limitations [49]. Therefore, fedbatch operation is applied to minimize high cell density related issues. Also, the fed-batch can
continue for a few days longer which increases the overall yield of recombinant protein and
dropping the production cost [51]. Fed-batch process like batch process, biomass, pH,
temperature, and dissolve oxygen can be monitored and controlled by a special bioreactor
software like Applikon BioXpert software.
2.7 Purification
There are an extensive amount of complicated details and specialized equipment
designed for protein isolation and purification. These pieces of equipment become more
convenient and automated. They are controlled by microprocessors and easy to operate [60].
Facilitating the production of high purity and well characterization of recombinant proteins is a
major task for the pharmaceutical industry [61].
Fast protein liquid chromatography (FPLC) has been widely used for purified
recombinant proteins. In short, cell lysate was loaded to the column filled with a cross-linked
resin that had ligands on its surface (depending on the target protein). The target protein then
interacted with the ligands on the surface of the resin and caused the rest of the lysate component
15

to wash away or caused a decrease in movement through the column. In the end, elution of the
target protein by washing the column with elution buffer which contains a type of material
triggering an interference of the binding of the target protein to the column resin. Purified protein
was then collected in small fractions for further analysis [59].
Affinity chromatography is a type of liquid chromatographic technique. To facilitate the
purification of recombinant protein, affinity tags have been genetically attached to targeted
protein. Typically, the DNA encoding for the additional tag or affinity tail is fused to a gene of
interest within the genes encoding for the target protein to express with the tag during
fermentation producing the protein of interest with affinity tag complex. Attaching a peptide
affinity tags to a recombinant protein has been widely used to facilitate protein purification using
several methods such as affinity, ion exchange, hydrophobic, covalent, and metal-chelating
separations [62]. This strategy can provide a high level of purification with a hundred- or even
thousand-fold more of using traditional affinity methods [63]. Polyhistidine tag (His6-tag) is an
example of an affinity tag which has been broadly used to facilitate recombinant protein
purification. It is also known as Immobilized Metal Affinity Chromatography (IMAC). Histidine
has a strong affinity to immobilized metal ions such as cobalt, copper, and zinc with +2 ionic
charge. The basic principle of this interaction is that histidine has an imidazole ring that can form
strong pi interaction bonds with the metal ions [64]. His6-tag is also used as an expression
marker by using a commercially available His6 antibody. Purification using this method can
produce 90-99% pure targeted protein from the original cell lysate [61, 65, 66].
2.7.1 General principles of affinity chromatography
Affinity chromatography is a type of liquid chromatographic technique which is a
stationary phase that is used for the purification or analysis of a solute in sample components
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made mostly from a biological related agent. In this method, specific reversible interactions that
occur in many biological systems such as the binding of an enzyme with a substrate or an
antibody with an antigen is used in the retention of a solute [67]. There are a surplus of natural
and synthetic molecules of non-biological origin which have also been used in affinity
separations. Regardless of their origin, all these ligands can be placed into one of two categories:
high-specificity ligands or general ligands. Ligands that are commonly used in affinity
chromatography are listed in Table 2.1.
Table 1.1 Common ligands used in affinity chromatography [68].

The base of these interactions is accomplished by placing one of a pair of interacting
molecules onto or within a solid support as an immobilized agent which is used in the stationary
phase. This support should have low non-specific binding for sample components, it should be
easy to modify for ligand attachment, and it should be stable under the flow rate, pressure, and
solvent conditions that will be employed in the analysis or purification of samples. Depending on
which affinity chromatography performance is used a low- or a high technique, there are several
types of support materials such as a carbohydrate-based gel or one of several synthetic organicbased polymers. This immobilizing agent is known as the affinity ligand which provides the
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affinity column the ability to interact or bind to compounds in a sample [68]. There are two
methods for solutes elution isocratic and gradient. A step gradient for elution is the most
common methods used in performing affinity chromatography by injecting a sample onto the
affinity column in the presence of a mobile phase that has the right pH and solvent composition
for specific solute–ligand binding [21]. This solvent, which represents the weak mobile phase, is
called the application buffer of the affinity column. While the sample is carried through the
column by the application buffer, target compounds bind to the affinity ligand due to the high
selectivity of the solute–ligand interaction. The other components of the sample tend to pass
through the column without being retained. After the non-retained components are washed
completely from the column, the elution step is performed to retain the target a solute using a
solvent that displaces them from the column by dissociating a solute–ligand complex interaction
(Figure 2.6). This solvent which represents the strong mobile phase for the column is called an
elution buffer. After the interesting solutes elute from the column, measurement are preformed
for detection purposes or a sample is collected for future use [68].
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Figure 2.6 Affinity chromatography binding and elution using antibody as an affinity agent. The
filled circles represent the test analyte, and the open squares represent another non-retained
sample [68].
2.8 Wound Healing
Wound healing is a normal biological process in the human body to repair an injured
tissue or skin. It is achieved through four highly programmed phases in proper sequence and
specific time: hemostasis, inflammation, proliferation, and remodeling. A brief summary of
cellular and bio-physiological events of wound healing process is shown in Table 2.2. These biophysiological events are regulated by several complex biological mediators including
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platelets, inflammatory cells, cytokines, growth factors, as well as matrix metalloproteinases and
their inhibitors [69, 70]. For a typical wound healing outcome, all four phases must occur in the
proper sequence.
Table 2.2 Normal wound healing phases, major types of cells involved in each phase, and
specific events involved [70].

Wound healing can be a simple break in the epithelial integrity of the skin or deeper
extending into subcutaneous tissue causing damage to other tissues such as tendons, muscles,
vessels, nerves, parenchymal organs, and even bone. However, wound healing is classified into
two major types: chronic and acute. In the acute type, wounds are healed normally through
undergoing a complex interactive process involving a variety of cells.
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On the other hand, chronic types proceed through portions of the repair process causing
improper tissue repair results [71]. This type of wound healing process is affected by many
factors such as oxygenation, infection, age and sex hormones, stress, diabetes, obesity,
medication, alcoholism, smoking, and nutrition. Understanding the effect of these factors on
repair may lead to developing new therapeutics that improve wound healing and resolve
impaired wounds [72]. Typical therapeutic wound healing implants should have the ability to
adhere and conform to the wound site, enable regrowth of epidermis, aid in the accumulation of
fibroblasts, endothelial cells, and wound healing regulatory cells into the wound site to speed the
healing process [73].
Wound healing largely remains a difficult pathology challenge in defeating related
clinical issues. To reduce the wound burden, several synthetic and biological materials have been
used to mediate tissue regeneration. Despite the advantages of using these materials to speed up
the healing process, it can generate several issues like infection issues such as compatibility and
infection considering the biological materials or the tissue from donors [74]. Looking for
alternative bioactive material is essential because it has the ability to enhance the tissue
regeneration process without the use of synthetic materials or the dependence of donors [75]. It
has been found that some material such as growth factors can activate cellular regeneration. The
main issue with this alternative is that it cannot be administered through usual drug delivery
methods due to their limited target specificity and short half-lives in vivo [76]. Many therapeutic
strategies have been used such as collagen in tissue engineering to aid in wound healing. It has
been found that collagen can provide structural stability and increase cellular attachment [74]. To
achieve a great deal of triumph and reduce both problems of specificity and short half-lives,
growth factors have been fused to collagen binding domains (CBD) and produced in E. coli. In
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this versatile therapeutic protein, the binding domain can be used as an “anchoring unit” for in
vivo applications and maintaining growth factor activity and its concentration at the target site
[77]. It has been shown that growth factors and cell binding peptides fused to biomaterial carriers
can achieve biomolecular recognition of cells in addition to interacting with surrounding tissues
[75]. Therefore, new therapeutic approaches have been designed in this project to produce basic
fibroblast growth factors fused to two units of collagen-binding domain (bFGF-CBD-CBD) with
a protease cleavage site between FGF and CBD as recombinant protein to care for both acute and
chronic wounds.
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3. Scope of the project
Since there is significant interest in explaining the use of FGF fusion proteins, this project
has been designed to express and purify a fusion of FGF with two collagen binding domain
(CBD). This project has been designed in to express, produce, and purify an innovative
therapeutic protein by fusing basic fibroblast growth factor to two units of collagen-binding
domain (bFGF-CBD-CBD) with a protease cleavage site between FGF and CBD units to care for
both acute and chronic wound. Two collagen binding domains (CBD) allows for efficient uptake
growth factors and deliver it to the wound site. After FGF is delivered to wound site, it can be
released from the CBD units by protease action.
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4. Materials and Methods
4.1 Strain and plasmid construction
E. coli BL21 (DE3) strain was purchased from New England Biolabs Inc and used as a
host to produce targeted recombinant protein. For expression plasmid construction, the
pBAD/Myc-His plasmid was purchased from Invitrogen Life Technologies. The pBAD/Myc-His
vector is a pBR322-derived expression vector. The araBAD promoter (P bad) provides tight,
dose-dependent regulation of heterologous gene expression (Guzman et al., 1995) because the
araC gene encodes the regulator protein for tight regulation of the P bad promoter (Lee et al.,
1981). Ampicillin resistance gene lactamase allows selection of the plasmid with an antibiotic.
Restriction maps and multiple cloning sites (MGS) of the plasmids are presented in Appendix 81 and the DNA sequence of PAEM-1 as well.
E. coli chemically competent Bl-21 cells from Invitrogen were used. Competent cells
were transformed with recombinant pAEM-1 plasmid. This plasmid, pAEM-1, contains the
genetic information for the recombinant protein bFGF-CBD-CBD (424 amino acids), as depicted
in Figure 4.1. Synthesized DNA sequence for bFGF-CBD-CBD protein was purchased from IDT
and cloned into pBAD expression vector.

24

Figure 4.1 Plasmid map of pAEM-1.
4.2 Cloning of target gene
Heat shock method was used for transformation of pAEM-1 to E coli-BL21. Gene of
interest and pBAD have the same restriction sites. The process starts by adding 20 μL of the
plasmid in three different tubes containing NcoI + EcoRI (1-3 µl from each enzyme) and 2.5µl of
10× of digestion buffer. The samples were incubated for 1 hour at 37°C and then subjected
agarose gel electrophoresis to validate restriction. The digested plasmid and target gene were
recovered from the gel to provide material for ligation. Samples were heated at 65°C for 10
minutes to denature restriction enzymes. Then, 8 µl of recovered plasmid from gel, 2 µl of
recover gen from gel, 1 µl ligase enzyme, 2.5 µl ligase buffer, and 1.5 µl of ddH2O were added
was mixed in one tube and incubate at 16°C overnight. To validate the ligation process, agarose
gel electrophoresis was performed. Two bands indicate a negative result.
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Transformation of a plasmid carrying the target gene to E. coli was done by heat shock
method as mentioned earlier. E coli-BL21 strain tube containing 20 ul of bacteria was taken from
-80 and incubate for 30 minutes in ice to thaw. After that, 2 - 5 µl of plasmid was added to the E
coli-BL21 strain and incubate in ice for another 30 minutes. The mixture was incubated exactly
for 10 seconds at 42°C and then placed on ice for 5 minutes. Transformed bacteria was mixed
with 1ml SOC outgrowth medium (New ENGLAND BioLabs, USA) without ampicillin and
incubated in a shaker incubator for 1 hour. After the incubation time was over, 100 µl was spread
on ampicillin containing LB agar media and incubated at 37°C for overnight. The presence of
colonies on ampicillin containing LB agar proved that the plasmid successfully transformed of E.
coli. A single colony was used to inoculate 5ml of ampicillin containing LB media and incubate
at 37°C for overnight.
4.3 Plasmid recovery and validation
To prove that bacteria up took the same plasmid, the plasmid was recovered from
bacteria, and gel electrophoresis showed the size of the engineered plasmid. Plasmid recovery
was done by using Plasmid Mini Kit purchased from Qiagen. The protocol was provided by
manufacturer. The process starts by inoculating 5 ml of LB media with 100µg/ml ampicillin and
incubating at 37°C overnight. Cells were collected by centrifugation at 14000 rpm for three min.
Plasmid extraction protocol was followed this step to collect recovered plasmid. A part of
recovered plasmid was subject to run through agarose gel electrophoresis for validation.
4.4 Media and expression of targeted protein
Luria-Bertani (LB) broth was used for all plates and seed cultivations. A single colony of
E. coli BL21 with pBAD Sakon Collagenase Eco47III spanning plasmid was picked from a plate
and inoculated a 50 ml sterile tube containing 10 ml of LB media supplied with 75 μg/ml
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ampicillin as an initial growth seed culture. The culture was incubated at 37 °C and shaken at
250 rpm overnight. The goal of using multiple types kind of cultivations was to monitor growth
and protein expression using both open and closed systems.
4.4.1 Traditional shake flask
This experiment was performed by using 2.5 ml of shake flask overnight to culture the
inoculated 500 ml of the media in every shake flask experiment. The growth was kept at a
temperature of 37 °C. Media was supplemented with 75 μg/ml ampicillin. L-arabinose was used
to induce the plasmid at the mid-exponential phase of growth to start expression when the optical
density (OD) reached ̴ 0.6 units (at 600 nm) about 2 hours from inoculation. Cells were collected
after 4 hours from induction to proceed in further steps.
4.4.2 Fed-batch cultivation
This trial was set as a primary experiment for a future scale-up plan. 10 ml of shake flask
culture was used to inoculate 100 ml of the media overnight. The following day, the 100 ml of
shake flask culture which had grown at 37 °C used to inculcate 3 L of bioreactor tanks loaded
with 1 L of LB media supplemented with 100 μg/ml ampicillin to maintain selection. Inducer (LArabinose) was added when optical density (OD) reached ̴ 0.6 units (at 600 nm). One liter of LB
media supplemented with 100 μg/ml ampicillin, 2mg/ml of magnesium chloride, 10 ml of
sterilized glycerol solution and L-Arabinose was included for inducing more growth cells in all
of the fed-batch experiments. The fed media was also supplemented with 1 ml antifoam to
control foaming and an additional few drops was deemed necessary when the foam reached a
level about 2 inches from the top of the reactor.
Each experiment can be broken down into a batch and a feeding phase. In the batch
phase, no additional nutrients were added to the reactor. After approximately 7 hours, the feeding
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phase began. Fed start point had been set depending on how efficient and how quickly the
growing bacteria reached the lag phase using only the initial carbon substrate in the start media.
An increase in pH and a sharp decline in dissolved oxygen level indicated that most carbon
sources were consumed in the system. In the fed-batch experiments, these events occurred at the
same time and were monitored by the Applikon bioreactor software. These two events that had
been observed happened between 7 to 8 hours after inoculation, so the feeding is started at a
specific time frame to provide more nutrients. In this experiments E coli-BL21 was used as a
host, and a shorter lag phase (2.5 hours) was observed. The feeding began around 7 hours from
bioreactor inoculation. Using different hosts may change the time that bacteria take to reach the
lag phase. For example, if the bacteria take 4 hours to reach a long lag phase, the feeding should
begin at 8 hours from inoculation.
The feeding profile that is proposed by Korz et al. (1995) and Lee et al. (1997) was used
in this experiment and was programmed into the Applikon software. Cells were collected after
20 hours from induction to proceed with further steps.
4.5 Cell lysate preparation
After fermentation, cells were collected by centered at 4 °C, 4,500 rpm for 45 minutes. 1 ml of
bacteria pellet resuspension was added in 5 ml of 10 mM of phosphate buffer with 0.5µl of a
cocktail protease inhibitor. Buffer to pellet ratio was kept constant and was then determined by
pellet volume. Sonicator was used to prepare cell lysate. This process was performed by lysate of
the cell in an ice bath. The lysate cell was and spun again by a centrifuge machine with the same
speed and condition. The solid fraction was discarded, and the lysates were kept at -20 °C. Then,
the sample was centrifuged for 5 minutes. The supernatant was collected and filtered once more
by using a 0.22 μm syringe filter. The filtered sample was subjected to the purification step.
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4.6 His6-protein purification
Lysates were purified using the Fast protein liquid chromatography (FPLC) system from
ӒKTA Amersham Pharmacia Biotech (Figure 4.2).

Figure 4.2 Fast protein liquid chromatography (FPLC) system (Image by author).
Cell lysates were filtered through a 0.20 μm filter. HiTrap IMAC FF columns from GE
Healthcare-Bio-Sciences (Uppsala, Sweden) were loaded with nickel. This column is received
with 20% ethanol as a preservative. Ethanol was washed away with sterile distilled water and
was loaded with 0.2 M nickel sulfate, then washed again with sterile distilled water and
equilibrated with 10 mM of sodium phosphate buffer (buffer A) for loading and binding, which
resulted in a pH of 7.3. Lysates were loaded at 0.5 ml/ min to ensure proper binding of His6tagged-protein. After 5 to 10 column volumes (CV) of washing (until the baseline returned to
zero), a gradient purification procedure was performed for elution of His6-tagged-protein using
250 mM Imidazole 10 mM of sodium phosphate buffer, pH=7.3 (buffer B). Collected fractions
were then stored at -20° C for further validation.
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4.7 Target protein determination assay
To ensure that the targeted protein expressed and produced properly by the host, the
collected fraction was subjected to a protein analysis experiment. Fractions were running through
a SDS-PAGE electrophoresis experiment. The gel then proceeded to detect His6-tag-proteins by
two methods; western blotting and the His6-tag fluorescent kit.
4.7.1 SDS-PAGE electrophoresis
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis is a technique used to
separate proteins depending on their molecular mass. In short, SDS binds to denatured protein,
and it is believed to adopt a negative charged rod-like shape. After that, an electrical field forces
a negatively charged protein to migrate through the gel from a negative to a positive electrode.
Proteins separate in different bands depending on their molecular mass difference. Different
thicknesses and concentrated gels were prepared that were dependent on the experiment and
protein separation purpose. The gel is prepared in two layers, resolving and stacking gel.
Resolving gel is used to stock the major component that is used to prepare both gel layers
include:


30 % Acrylamide



1 M Tris – HCl, pH 8.8 for resolving and 0.5 M Tris – HCl, pH 6.8 for stacking gel



10 % SDS



Deionized water



10 % APS



TEMED

Denaturation of the protein is a necessary step, before loading and running of protein
samples in the gel, protein samples are denatured by mixing with 2X loading dye which contains
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5% of 2-mercaptoethanol to reduce protein superficial and intermolecular disulfide bonds
between protein subunits. The solution is then heated for 5 minutes at 95 °C right before added
to the polyacrylamide gel. Electrophoresis was performed in an electrophoresis chamber filled
with SDS-PAGE buffer by applying 180 volts for 50 minutes. After completing electrophoresis,
the gel was rinsed by deionized water. The gel was placed in Coomassie staining buffer for 30
minutes and left overnight to see the separated protein bands directly or subjected for further
processing for further advancement of targeted protein validation.
4.7.2 Detection of His6-tag using protein tag stain reagent set
Pierce™ 6xHis Protein Tag Stain Reagent Set was purchased from ThermoFisher
Scientific reagents. This kit is a fluorescent stain which is able to detect histidine-tagged (Histagged) recombinant fusion proteins in polyacrylamide gels. His-tagged recombinant proteins
can be detected directly in the gel. The entire protocol takes 140 minutes. This method eliminates
time-consuming membrane transfers when using a western blotting technique that is typically
used to detect and confirm the purity of tagged proteins. After the procedure is done, his6-tagprotein was detected using a UV lamp (300nm) or a type of detection equipment (CCD camera).
A CCD camera is used in this study because it is more sensitive and can detect as low as 0.2 µg
of His-tagged protein. Another advantage is that it uses the same gel for a total protein profile
determination by staining with Coomassie protein dye.
4.7.3 Western blot
After proteins are separated based on molecular weight through SDS-PAGE gel
electrophoresis, separated proteins transfer to a membrane to detect targeted proteins with the
specific antibody. Samples, protein markers, and a positive control run with two SDS-PAGE
gels, one gel for direct staining and another for protein transfer. After electrophoresis was
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completed, the nitrocellulose membrane and the transfer gel were equilibrated in the transfer
buffer and assembled in a blotting stack in order (as shown in assemble step in Figure 4.3).

Figure 4.3 Steps of western blot gel preparation and stock diagram [78]
The stack unit is then placed in the tank which is filled with transfer buffer (1X Towbin
with 20% methanol). After this step, the power supply was connected and was set at 150V, 74
mA for 2 hours. After blotting was completed, nitrocellulose membrane was a sock in 5% of
skim milk TBS-T freshly prepared for 30 minutes to block the non-specific site. Then, the
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membrane was washed with TBS-T. The membrane was kept incubated overnight in a TBS-T
buffer containing His6-tag antibodies and 0.2% bovine serum albumin (BSA). The following
day, the membrane was washed three times for three minutes each time with TBS-T to remove
any excess antibodies. One milliliter of NBT/BCIP solution was added to a transfer paper. By
using a 1 mL pipette, the same solution was poured onto the membrane until the band developed.
To prevent the membrane from turning dark in color, the membrane was transferred into water to
halt the reaction.
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5. Result and discussion
5.1 Traditional shake Flask cultivation
In this experiment, two liters of LB media supplied with 100 μg/ml ampicillin was
inoculated with 10 ml of overnight growth. After 2 hours, arabinose was used to induce the cell
to produce the protein of interest. Cells were harvested after 4 hours. A total of approximately 3
grams of cell pellets were lysed and then subjected to purification by IMAC using nickel loaded
HiTrap IMAC FF columns. IMAC chromatograms showed two peaks in 62.5 mM imidazole, as
well as one small one eluted in 125 mM imidazole (Figure 5.1).

Figure 5.1 FPLC chromatogram of cell lysate prepared by traditional shaker flask method using
nickel loaded HiTrap IMAC FF column.
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All fractions coming from these peaks were subjected to SDS-PAGE gel to check if the
protein of interest (bFGF-CBD-CBD) had appeared. The lysate and all suspected fractions were
covered in three gels. An equal volume from each IMAC fraction was loaded to each lane in the
15% SDS-PAGE gel. Gel stained with Pierce™ 6xHis Protein Tag Stain Reagent and Coomassie
Brilliant Blue staining solution showed several interesting bands in cell lysate and F# 25-29
(Figure 5.2).

Figure 5.2 SDS-PAGE gel shows IMAC fractions results of cell lysate prepared by the
traditional shaker method. A. Gels stained with Pierce™ 6xHis Protein Tag Stain Reagent. B.
Gels stained with Coomassie Brilliant Blue staining solution. Results for both methods included
lane 1– molecular weight marker; 2– cell lysate after expression; 3– junk protein fraction; 4– 12,
fraction 20-28 respectively.
The results of 62,5 mM imidazole fraction showed a strong his6x protein signal at
approximately 46 KD (figure 5.3).
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Figure 5.3 bFGF-CBD-CBD fusion protein carton shows the molecular weight of bFGF and 2
unit of CBD.
This band is equivalent to an expected molecular weight of bFGF-CBD-CBD. It also
showed a strong Hisx6 tag protein signal at approximately 28 KD. Since the designed bFGFCBD-CBD protein has a collagenase cleavage site between bFGF and CBD-CBD-Hisx6, it is
interesting to note that another outcome is possible. Collagenase cleavage sites might be cleaved
by a protease which is naturally produced in E coli-BL21. If the bFGF is released from the entire
protein, the expected molecular weight of CBD-CBD-Hisx6 unit is 28 KD. Western blot was
performed to specifically detect Hisx6-tag protein using Hisx6-tag antibodies. As shown by the
western blot where the interesting fractions were run (Figure 5.4), two interesting bands; 46 KD
and 28 KD were shown over the lysate and fraction #25 to fraction #29.

Figure 5.4 Western blot of interesting IMAC fractions resulting in lysate prepared by traditional
shaker methods. 1 – molecular weight marker; 2 – positive control (Hisx6-tag -protein; 3–cell
lysate after expression; 4– junk protein fraction; 5 – 11, fraction 23 to 29 respectively.
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Fraction of 125 mM was also examinde using western blot. Bands were developed at 46
KD and 28 KD in fraction #3 and #4 (figure 5.5). Result of 125 mM fraction also confirm the
cleavage issue. This is an interesting finding that needs further investigation to validate.

Figure 5.5 Coomassie Brilliant Blue staining and Western blot of the interesting heparin
fractions of lysate prepared by traditional shaker methods. For both methods; 1 – molecular
weight marker; 2– positive control (Hisx6-tag -protein); 3- cell lysate; 4–10 fraction 1 to 7
respectively of 62.5 mM imidazole fraction.
5.2 Fed-batch cultivation
As mentioned previously in section 4.4.2, this method was used to produce high cell
density. In traditional flask methods, 1-2 grams per liter was yielded as the total dry cell weight
while 50-55 grams were produced by using fed-batch fermentation (Figure 5.6). In terms of
biomass production, there is a varying difference between the amount produced by fed-batch
fermentation (Figure 5.6 A) and shake flask method (Figure 5.6 B). Producing a large amount of
biomass has an advantageous impact on manufacturing cost. The production of more cells
subsequently results in a greater protein production yield.
In this method, feeding profiles were used by employing an exponential feeding strategy
as mentioned in Chapter 4. The main target of using this strategy is to produce a large number of
cells. Thus, resulting in a large amount of recombinant protein produced through fed-batch
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fermentation. This method is used in many industrial applications to achieve production target
with a large quantity.

Figure 5.6 Biomass production of E coli BL-21 by using; A- Fed-batch fermentation method; BTraditional shaker method (Image by author).
As discussed in section 4.4.2, the entire process breaks down into two events; batch and
fed-batch fermentation. In the batch step, L-arabinose was added to induce an expression of
BFGF-CBD-CBD protein after approximately 2 hours from inoculation when the optical density
(OD) reached ̴ 0.6 units (at 600 nm) to maintain the inducer availability to the new cells in the
next event (fed-batch step). Arabinose was supplied with feed by the same percentage. Cells
were collected after 18 hours from the time of induction. A total of 100 grams of dry cell weight
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was harvested from two liters growth in 3 liters of bioreactors. Cell lysate prepared by this
method was subjected to a purification step and followed by an expression examination. Gradient
purification protocol (which is described in chapter 4) was performed.
The outcome fractions of the IMAC purification technique (Figure 5.7) were examined to
confirm the engrossing recombinant protein (bBFGF-CBD-CBD-Hisx6) expression. As shown in
Figure 5.7, two peaks were shown in 62.5 mM imidazole fraction, and a small one is shown in
125 mM imidazole fraction. Both fractions were subjected to a validation process to check
targeted protein expressions using 15% SDS-PAGE gel. Similar to traditional flask culture, two
interesting bands 46 KD, and 28 KD, were shown in the gel over the lysate and fraction #11fraction #14 (figure 5.8). These bands are shown using both staining methods; Pierce™ 6xHis
Protein Tag Stain Reagent and Coomassie Brilliant Blue staining solution. As previously stated
in section 5.1, this result confirms the same scenario of two notable bands 46 KD, and 28 KD.
Since the 46 KD band looks small and resembles a tail buried under the other thick band (figure
5.8), suspected fractions (fraction 9-16) were concentrated using TCA protein precipitation
protocol. Concentrated fractions were then loaded to SDS-PAGE gel right before the protein was
transferred to a nitrocellulose membrane to perform the western blotting technique. The western
blotting result has confirmed the expression of Hisx6 tag-protein using specific Hisx6-tag
antibody (Figure 5.9).
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Figure 5.7 FPLC purification chromatogram of cell lysate prepared by fed-batch fermentation
using nickle-loaded HiTrap IMAC FF columns.

The result shows a thick His-tag protein band at 27KD in fractions #12-16 while a thin
band is shown at 46 KD in the same fractions. This result might confirm the bFGF cleavage
scenario from the whole expressed protein (BFGF-CBD-CBD). This scenario might happen after
the expression of the whole BFGF-CBD-CBD protein. Natural protease may occur by E coli and
cleave the collagenase site that was designed between the bFGF and Josh-Hisx6 unit. This
cleavage release of bFGF from the rest of the unit includes Hisx6-tag. As a result, two expected
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Figure 5.8 SDS-PAGE gel shows IMAC fractions of cell lysate prepared by the fed-batch
method. A. Gel stained with Pierce™ 6xHis Protein Tag Stain Reagent. B. Gel stained with
Coomassie Brilliant Blue staining solution. For both methods, lane 1 – molecular weight marker;
2 –cell lysate after expression; 3 –11, fraction 9 -16 respectively.
Hisx6-tag protein bands are shown in the gel at 28 KD and 46 KD. Most of the Hisx6-tag
protein is detected at 28 KD which also gives credit to support the cleavage scenario. His6x-tag
protein is shown at 28 KD. All fractions including the fraction in small peak were subjected to
the validation process to check if the whole protein (BFGF-CBD-CBD) undergoing the cleavage
process by the host after production.

Figure 5.9 Coomassie Brilliant Blue staining and Western blot of a riveting IMAC fraction of
the lysate prepared by the fed-batch method. For both methods. 1 – molecular weight marker; 2–
9 fraction 9 to 16 respectively; 10– positive control (Hisx6-tag -protein).
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5.3 Purification of BFGF-CBD-CBD protein by heparin affinity chromatography
It has been discovered that one of the most important classes of heparin-binding protein is
the fibroblast growth factors. Since the expressed protein in this study is fused to FGF, cell lysate
prepared by traditional flask methods was subjected to another purification strategy using HiTrap
Heparin HP to acquire more evidence to support the cleavage issue between bFGF and JoshHisx6 unit. Cell purification was performed by FPLC. Two peaks were shown in FPLC
chromatograms at 0.5 M NaCl fractions. Additionally, there was a small one that eluted in 1 M
NaCl fractions (Figure 5.10).

Figure 5.10 FPLC purification chromatogram of cell lysate prepared by the fed-batch method
using HiTrap Heparin HP column.
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The results in Figure 5.11 show that the 28 KD band which represent Josh-Hisx6 has
disappeared. This band showed Hisx6-tag protein signal in the previous experiment. This is also
accredited to support the cleavage issue given that the FGF (which has a high binding affinity to
heparin) is cleaved from the whole protein.

Figure 5.11 Coomassie Brilliant Blue staining and Western blot of the interesting heparin
fractions of lysate prepared by methods. For both methods; 1 – molecular weight marker; 2–
positive control (Hisx6-tag -protein); 3- 9 fraction 15–21 fraction.
As was produced in IMAC purification, the weak band was also shown at 46 KD in
fraction #15, #16 and #17. This is another confirmation of what happen to the whole units of
production. More investigations such as protein sequencing for suspected bands are necessary to
confirm the hypothesis of our explanation.
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6. Conclusions and Recommendation
In light of the findings of the present study, bFGF-CBD-CBD is expressed by E coli BL21 using traditional shake flask and fed-batch cultivations. This protein can be produced in large
amount if the major cleavage issue between CBD-CBD and bFGF can be solved. Sequencing of
suspected protein bands is important to confirm the cleavage event. Genetic studies are also
recommended to find the protease responsible for and knock-out its genes. Conducting further
studies by using other E. coli hosts with genetically improved expression to produce a high yield
of bFGF-CBD-CBD are necessary. Further biological studies are needed to evaluate the
biological efficacy of bFGF-CBD-CBD with cell culture studies.
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